Oncology News Central

2 days ago | oncologynewscentral.com | Leah Lawrence

Combining two bispecific antibodies, talquetamab and teclistamab, led to a higher overall response rate (ORR) with deep, durable responses among patients with multiple myeloma and extramedullary disease (EMD), according to the results of the phase 2 RedirecTT-1 trial presented at the European Hematology Association 2025 Congress (Abstract LB4001).

1 week ago | oncologynewscentral.com | Robert A. Winn |Robert A. Figlin

This transcript has been lightly edited for style and clarity. Robert A. Figlin, MD: Welcome, this is Bob Figlin, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. I’m delighted to visit with Bob Winn, who is the director and Lipman Chair in Oncology at VCU Massey Cancer Center and current president of the Association of American Cancer Institutes. Bob, thanks for joining us. Robert A. Winn, MD: Thank you for having me.

1 week ago | oncologynewscentral.com | Marcia Frellick

An oncologist leaving a rural network introduces unique stressors and coverage consequences. Authors of a new qualitative study interviewed oncologists in some of those areas to better understand what strategies may be used to help mitigate specialist shortages. Erika L. Moen, PhD, from the Department of Biomedical Data Science at Dartmouth College in Lebanon, New Hampshire, and colleagues interviewed 20 oncologists from five geographically diverse regions.

1 week ago | oncologynewscentral.com | Yelena Y. Janjigian |Robert A. Figlin

This transcript has been lightly edited for style and clarity. Robert A. Figlin, MD: Hello, this is Bob Figlin, the Steven Spielberg Family chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. And I’m delighted to have Dr. Yelena Janjigian, who is the chief of the Gastrointestinal Oncology service at Memorial Sloan Kettering (MSK) Cancer Center in New York City. Yelena, thanks so much for joining us today. Yelena Y. Janjigian, MD: It’s such an honor, Bob. Thanks so much for having me.

1 week ago | oncologynewscentral.com | Leah Lawrence

Post-transplant cyclophosphamide (PTCy) combined with cyclosporin significantly improved outcomes for patients with acute leukemia or myelodysplastic syndrome undergoing stem cell transplantation with a matched sibling donor, according to data from the BM12 CAST trial presented at the European Hematology Association 2025 Congress (Abstract S103) and published in the New England Journal of Medicine.